Andrew L. Faber

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

John D. Carpten, Andrew L. Faber, Candice L. Horn et al. · Nature · 2007 · 1.3K citations

Medicine, Molecular Biology, Oncology +12

Differences in Host Susceptibility to Disease Progression in the Human Challenge Model of<i>Haemophilus ducreyi</i>Infection

Stanley M. Spinola, Cliffton T. H. Bong, Andrew L. Faber et al. · Infection and Immunity · 2003 · 41 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Abstract 5245: Identification and characterization of the IDO1 inhibitor LY3381916

Frank C. Dorsey, Karim A. Benhadji, Lillian Sams et al. · Cancer Research · 2018 · 15 citations

Medicine, Immunology, Oncology +17

Abstract P142: Preclinical characterization of LOX-22783, a highly potent, mutant-selective and brain-penetrant allosteric PI3Kα H1047R inhibitor

Anke Klippel, Rui Wang, Loredana Puca et al. · Molecular Cancer Therapeutics · 2021 · 11 citations

Medicine, Oncology, Pharmacology +17

Abstract P4-08-02: LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3Kα H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3Kα H1047R-mutant breast cancer models

Loredana Puca, Michele Dowless, Carmen M. Perez-Ferreiro et al. · Cancer Research · 2023 · 10 citations

Medicine, Oncology, Pharmacology +15